Document Detail

Maternal plasma osteoprotegerin concentration in normal pregnancy.
MedLine Citation:
PMID:  16157103     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Pregnancy is associated with major changes in calcium metabolism because the neonatal skeleton contains approximately 30 g of calcium, which are largely deposited in the third trimester. Osteoprotegerin (OPG) acts as a decoy receptor for the "Receptor Activator of Nuclear Factor-kappaB Ligand" (RANKL), which is an essential factor for bone remodeling. This study was conducted to determine whether there were changes in maternal plasma OPG concentration during normal pregnancy.
STUDY DESIGN: A cross-sectional study was performed in 433 patients of reproductive age (40 nonpregnant and 393 pregnant). Pregnant patients were classified into 4 groups according to gestational age: group 1: 11 to 14 weeks (n = 100); group 2: 15 to 18 weeks (n = 99); group 3: 27 to 30 weeks (n = 100); and group 4: 37 to 42 weeks (n = 94). Plasma OPG concentrations were measured with the use of a sensitive and specific immunoassay. Nonparametric statistics were used for analysis.
RESULTS: OPG was detected in the plasma of all women tested. The median OPG concentration was significantly higher in term patients than in those in early pregnancy (median: 6.63 pmol/L [range: 1.57-25.57] vs median: 3.98 pmol/L [range: 0.41-13.71], P < .001). There was no significant difference in plasma OPG concentrations between nonpregnant women and those in groups 1 or 2 (nonpregnant women median: 3.86 pmol/L [range: 1.64-15.29] vs group 1 median: 3.98 pmol/L [range: 0.41-13.71] vs group 2 median: 3.87 pmol/L [range: 1.14-69.83], P = .75).
CONCLUSION: The median maternal plasma OPG concentration is higher in the third trimester than in the first trimester of pregnancy. OPG may be involved in the regulation of bone turnover during pregnancy.
Joon-Seok Hong; Joaquin Santolaya-Forgas; Roberto Romero; Jimmy Espinoza; Luís F Gonçalves; Yeon Mee Kim; Samuel Edwin; Bo Hyun Yoon; Jyh Kae Nien; Sonia Hassan; Moshe Mazor
Related Documents :
3955123 - Plasma vasopressin concentrations and serum vasopressinase activity in pregnant and non...
1312543 - Mineralocorticoid effector mechanism in preeclampsia.
9509983 - Transforming growth factor beta and the endometrium.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  193     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-09-13     Completed Date:  2005-10-26     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1011-5     Citation Subset:  AIM; IM    
Perinatology Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Sectional Studies
Gestational Age
Glycoproteins / blood*
Pregnancy / physiology*
Pregnancy Trimester, First
Pregnancy Trimester, Third
Receptors, Cytoplasmic and Nuclear / blood*
Receptors, Tumor Necrosis Factor / blood*
Grant Support
Z01 HD002400-14/HD/NICHD NIH HHS
Reg. No./Substance:
0/Glycoproteins; 0/Osteoprotegerin; 0/Receptors, Cytoplasmic and Nuclear; 0/Receptors, Tumor Necrosis Factor; 0/TNFRSF11B protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of phosphodiesterase 5 in maternal and fetal sheep.
Next Document:  The MFMU Cesarean Registry: factors affecting the success of trial of labor after previous cesarean ...